Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers
NCT ID: NCT01599897
Last Updated: 2017-09-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
60 participants
INTERVENTIONAL
2012-08-31
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2 µg ID93 + 2 µg GLA-SE
Low dose and antigen and low dose of adjuvant.
ID93 + GLA-SE
ID93 antigen and GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
10 µg ID93 + 2 µg GLA-SE
High dose of antigen and low dose of adjuvant.
ID93 + GLA-SE
ID93 antigen and GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
2 µg ID93 + 5 µg GLA-SE
Low dose of antigen and high dose of adjuvant.
ID93 + GLA-SE
ID93 antigen and GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
10 µg ID93 + 5 µg GLA-SE
High dose of antigen and high dose of adjuvant.
ID93 + GLA-SE
ID93 antigen and GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
2 µg ID93 alone
Low dose of antigen alone.
ID93 alone
ID93 antigen alone. 3 injections and Days 0, 28, and 56.
10 µg ID93 alone
High dose of antigen alone.
ID93 alone
ID93 antigen alone. 3 injections and Days 0, 28, and 56.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ID93 + GLA-SE
ID93 antigen and GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
ID93 alone
ID93 antigen alone. 3 injections and Days 0, 28, and 56.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female who is 18 to 45 years of age at the time of randomization
* Agrees to stay in contact with the study site for the duration of the study, provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study
* Agrees to avoid elective surgery for the full duration of the study
* For female subjects: agrees to avoid pregnancy through Study Day 238. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Acceptable methods of avoiding pregnancy include a sterile sexual partner, sexual abstinence (not engaging in sexual intercourse), hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring, intrauterine device (IUD), condoms or the combination of diaphragm with spermicide
* Has body mass index (BMI) between 19 and 33 (weight/height2) by nomogram at the time of randomization
Exclusion Criteria
* Oral temperature greater than 37.5C (99.5F) at the time of randomization
* Values for any of the following screening laboratory parameters, from blood collected within 15 days prior to randomization, outside the normal ranges per local laboratory parameters: hemoglobin, hematocrit, absolute neutrophil count, absolute lymphocyte count, white blood cell count, electrolytes, ALT, AST, total bilirubin, alkaline phosphatase (ALP), creatinine, BUN, and lipid profile
* Evidence of systemic or local disease process on screening urinalysis
* Evidence of significant active infection
* Positive laboratory test (e.g., QuantiFERON(R)-TB) evidence of Mtb infection at screening
* History of treatment for active or latent tuberculosis infection
* History or evidence of active tuberculosis
* Has received vaccination or immunotherapy with a BCG product at any time prior to randomization
* Shared a residence within the last year prior to randomization with an individual on anti-tuberculosis treatment or with culture or smear positive tuberculosis
* History of or evidence of current hypertension
* History of autoimmune disease or immunosuppression
* Used immunosuppressive medication within 42 days before randomization (inhaled and topical corticosteroids are permitted)
* Received immunoglobulin or blood products within 42 days before randomization
* Received any investigational drug therapy or investigational vaccine within 182 days before randomization, or planned participation in any other investigational study during the study period
* Received investigational Mtb vaccine at any time prior to randomization
* Unable to discontinue current chronic prescription drug therapy including hormone replacement such as thyroxin, insulin, and medications that can be hepatotoxic or toxic to the bone marrow (such as statins) etc (estrogen and progesterone replacement and contraceptives, topical medications, and nasal steroids are acceptable)
* History or laboratory evidence of immunodeficiency state including but not limited to laboratory indication of HIV 1 infection at screening
* History of allergic disease or reactions (such as an allergic reaction to eggs), including eczema, likely to be exacerbated by any component of the study vaccine
* History of allergic reaction to kanamycin-related antibiotics
* Previous medical history that may compromise the safety of the subject in the study, including but not limited to: severe impairment of pulmonary function from tuberculosis infection or other pulmonary disease; chronic illness with signs of cardiac or renal failure; suspected progressive neurological disease; or uncontrolled epilepsy or infantile spasms
* History of positive tuberculin skin test
* Evidence of chronic hepatitis (e.g., hepatitis B core antibody or hepatitis C antibody) at screening
* History of alcohol or drug abuse within the past 2 years or consumes more than 1 (women) or 2 (men) alcoholic beverage(s) per day
* Tobacco or cannabis smoking 3 or more days per week
* History of keloid formation
* Positive urine test for illicit drugs (opiates, cocaine, amphetamines) at screening
* History or evidence on physical examination of any systemic disease or any acute or chronic illness that, in the opinion of the investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine, including axillary lymphadenopathy
* All female subjects: currently pregnant or lactating/nursing; or positive urine pregnancy test during screening or positive urine pregnancy test on the day of study injection
* Received a tuberculin skin test within 3 months (90 days) prior to the time of randomization
* Any current medical, psychiatric, occupational, or substance abuse problems that, in the opinion of the investigator, will make it unlikely that the subject will comply with the protocol
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aeras
OTHER
Paul G. Allen Family Foundation
OTHER
Access to Advanced Health Institute (AAHI)
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Franco Piazza, MD, MPH
Role: STUDY_DIRECTOR
Access to Advanced Health Institute (AAHI)
Anna Marie Beckmann, PhD
Role: STUDY_DIRECTOR
Access to Advanced Health Institute (AAHI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johnson County Clin-Trials
Lenexa, Kansas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Coler RN, Day TA, Ellis R, Piazza FM, Beckmann AM, Vergara J, Rolf T, Lu L, Alter G, Hokey D, Jayashankar L, Walker R, Snowden MA, Evans T, Ginsberg A, Reed SG; TBVPX-113 Study Team. The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. NPJ Vaccines. 2018 Sep 4;3:34. doi: 10.1038/s41541-018-0057-5. eCollection 2018.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IDRI-TBVPX-113
Identifier Type: -
Identifier Source: org_study_id